Among them, EML4-ALK fusion gene was detected in 34 patients (Figure 2), the positive rate was 8.52% (34/399), the positive rate in adenocarcinoma was 11.62% (33/284), and the positive rate in squamous cell carcinoma was 0.86% (1/115). The gene discussed is ALK; the disease is adenocarcinoma.